Of both interest and importance, our preclinical results, in general, are in line with recent clinical data from phase III trials involving both the use of a doublet treatment combining PD-L1 therapy and Nab paclitaxel to treat metastatic TNBC [63], and of a triplet therapy involving antiangiogenic, chemo- and immunotherapeutic (PD-L1 antibody) drugs, albeit for metastatic NSCLC [80]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.